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BACKGROUND AND INTRODUCTION
Human papillomavirus (HPV) infection is a preventable yet common cause
of morbidity and mortality with more than 14 million new cases per year in
the U.S.1 HPV causes nearly all cervical cancers and many vaginal, vulvar,
anal/rectum, penile, and oropharyngeal cancers.2,3 Approximately 1 in 4
people in the U.S. are currently infected with HPV, and nearly 80% of people
will develop HPV during their lifetime.1
The HPV vaccine can prevent HPV infections that cause HPV-associated
cancers. The Advisory Committee on Immunization Practices (ACIP)
recommends initiation of the HPV vaccination series during early
adolescence between ages 11 and12 years for both males and females.4
Despite safety of the vaccine5, endorsement from professional
organizations such as ACIP4, and a Healthy People 2020 HPV vaccine
series completion goal of 80%,6 HPV vaccine uptake rates remain
suboptimal. At the time of this study, national HPV vaccination initiation
rates for ages 13 and 17 years were 53.5% and 65.4%, respectively.7
Though evidence-based strategies have been developed to increase
uptake of other vaccines,8 interventions aiming to increase HPV vaccine
use have demonstrated limited impact.9,10 Evidence-based strategies to
increase HPV vaccination rates include provider assessment and feedback
, provider cues, patient reminders, and delivering bundled vaccine
recommendations, but using any one of these strategies in isolation is less
effective than applying multiple strategies.8 Theory- and evidence-based
interventions can optimize effectiveness for individual and organizational
change.11 The Adolescent Vaccination Program (AVP) is a theory- and
evidence-based multilevel and multicomponent HPV vaccination
intervention comprising sequential rollouts of system-level strategies. A
recent quasi experimental study of the AVP, conducted in a large urban
southwestern pediatric clinical network, demonstrated its success in
significantly increasing HPV vaccination initiation and completion rates over
a 3-year period (p ≤ 0.05).12
Intervention Mapping (IM) is a systematic approach to planning theory- and
evidence-based health promotion interventions.13 A recent systematic
review demonstrated significant increase in the uptake of disease
prevention behaviors associated with IM-based interventions when
compared to placebo control groups.14 IM has been used to develop
interventions for preventing cancer, including skin,15 lung,16 breast,17 and

Published by DigitalCommons@TMC, 2019

1

Journal of Applied Research on Children: Informing Policy for Children at Risk, Vol. 10 [2019], Iss. 2, Art. 9

cervical17-20 cancers. A recent study reported the use of IM to develop an
HPV vaccination behavioral education intervention for parents of Hispanic
adolescents.21 However, few applications of IM have been reported in the
context of developing a multicomponent intervention that have comprised
vaccination strategies targeting clinics, providers, and parents.21 The
purpose of this paper is to describe the application of IM in the development
of the theory- and empirically based AVP to increase HPV vaccination rates.
METHODS
Intervention Mapping
IM is a stepped framework to guide the development of behavioral change
interventions that enable developers to systematically apply social and
behavioral science theories.22 The 6 steps of IM (Table 1) are to: 1) assess
needs and develop a logic model of the problem, 2) develop matrices of
behavioral change objectives for the program, 3) identify theory-based
methods and practical applications to be applied in the program, 4) produce
program components and materials, 5) plan for program adoption,
implementation, and sustainability, and 6) plan for evaluation.13 This project
was approved by The University of Texas Health Science Center at Houston
Institutional Review Board (HSCSPH-14-0725).
The Development Timeline
Completion of the IM development process encompassed 2 years of
activities (Table 1). The first 6 months of Year 1 involved development of
the logic model of the problem (IM Step 1), defining program outcomes and
objectives and matrices of change (IM step 2), and instituting the
vaccination champion component to advocate for and mediate the
implementation of the AVP within the clinic sites (as an advocate and
mediator for the AVP). The remaining 6 months of Year 1 involved program
planning, developing the AVP design document (IM Step 3), and initial
rollout of the assessment and feedback strategies. Year 2 involved
completing the full program prototype, including development cycles for
each component followed by a formative evaluation with pilot testing of
components (IM step 4). Plans for implementation and evaluation (IM Steps
5 and 6) were consolidated during the period of AVP formative testing and
were implemented from 2015 through 2018.
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TABLE 1: Intervention Mapping (IM) Steps with Associated Tasks and AVP Deliverables
Yr
1

IM Steps
1. Assess need and
develop a logic
model
of the problem
2. Develop
matrices of change
objectives and a
logic model of
change

3. Identify theorybased methods
and practical
applications for
program design
2

4. Produce
program
components and
materials

5. Plan for program
adoption,
implementation,
and sustainability
6. Plan for
evaluation
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IM Tasks
• Establish and work with a planning group.
• Describe the context for the intervention, including the
population, setting, and community.
• Conduct a needs assessment to create a logic model of the
problem.
• State expected outcomes for behavior and environment.
• Specify performance objectives for behavioral and
environmental outcomes.
• Select determinants for behavioral and environmental
outcomes.
• Create a logic model of change.
• Construct matrices of change objectives.
• Generate program themes, components, scope, and
sequence.
• Choose theory- and evidence-based methods to create
change.
• Select or design practical applications to deliver change
methods.
• Refine program structure and organization.
• Prepare plans for program materials.
• Draft messages, materials, and protocols.
• Pretest, refine, and produce materials.

• Identify potential program implementers.
• State outcomes and performance objectives for
implementation.
• Construct matrices of change objectives for implementation.
• Design implementation interventions.
• Write effect and process evaluation questions.
• Develop indicators and measures for assessment.
• Specify evaluation design.

Development Deliverables
• Clinic Provider Advisory Group
• Literature review – evidence table
• PRECEDE Model

• Matrices for provider outcome behaviors comprising 8
performance objectives and 65 learning objectives.

• Conceptual model for the AVP (model of change).

• AVP design document comprising specifications including:
content, design features, functionality, language, logistics of use
and implementation in the clinic, orientation needs, and evaluation
specifications.
•
•
•
•
•
•
•

AVP Champion webinars (n=4).
AVP Champion Binders for each clinic.
Provider assessment and feedback reports.
Provider continuing education module.
EHR Best Practice Advisory for HPV vaccination.
Pediatric Wellness Registry for patient HPV vaccination reminders.
Pilot test protocols and results:
• Manual of Procedures.
• AVP component feasibility testing in advisory clinics.
• Processes and channels for deployment of AVP strategies.
• Matrix of key stakeholders / gatekeepers for implementation.

• Evaluation Design Manual of Procedures, including:
• Study hypotheses and protocols.
• Measures for assessment.
• Baseline and follow-up surveys for physicians and clinic staff.
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IM STEP 1: LOGIC MODEL OF THE PROBLEM
Step 1 comprised the following: establishing a planning group; conducting
a needs assessment informed by the PRECEDE (Predisposing, Reinforcing
and Enabling Constructs in Educational Diagnosis and Evaluation) planning
model that outlines the factors associated with the problem; defining the
context of the intervention in terms of population, setting, and community;
and starting to implement program goals.13
Task 1.1: Establish and work with a planning group
Pediatric clinic population and setting. The AVP development involved
collaboration with a large urban pediatric clinic network in the southwestern
United States. The network comprised 51 pediatric practices in 5 counties
(encompassing over 220 physicians and over 800 staff members), serving
an estimated 20% of the pediatric population in these counties. Clinics
varied in size, staff composition, patient demographics, and rates of
initiation of HPV vaccination. Most clinics (97%) were certified by the
National Committee for Quality Assurance (NCQA) and, where eligible,
were NCQA-recognized medical homes. Five clinics were located in
underserved areas and provided pediatric medical services for families who
would otherwise receive limited or no health care due to low family income
or lack of health insurance. The network participated in Healthcare
Effectiveness Data and Information Set (HEDIS) accreditation.23 Patient
demographics comprised white (59%), Hispanic (23%), African-American
(13%), and Asian (5%). Most patients (73%) had commercial insurance; the
rest had Medicaid (17%), Children’s Health Insurance Plan (CHIP) (6%), or
no insurance (4%). Approximately 25% were eligible for the Vaccines for
Children (VFC) program.
Stakeholder Advisory Committee. The IM process recommends
identification of key stakeholders, including experts, community members,
potential implementers, leaders, and members of the population of interest,
to form a planning group that guides intervention development.13 The AVP
stakeholder advisory committee (SAC) comprised 3 researchers in HPV
and cancer prevention, behavioral science, and intervention development,
3 pediatricians, 1 pediatric information technologist, 1 data analyst, and
leaders of the network, including the chief medical officer (CMO). The CMO
identified a core of 6 advisory clinics with diverse geographic locations and
mixed patient demographics and insurance payer base (private vs. public)
to enable broad access to “frontline” providers for formative assessments
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of the AVP components prior to implementation. The CMO, an
administrator, and the project team held regular biweekly in-person
meetings through the entire IM process to: plan and design components
(including review content, assess functionality, flow, and the “look and feel”
of AVP components); develop plans for seamless implementation (rollout)
without disruption to standard operating procedures; and plan for evaluation
activities.
Task 1.2: Conduct a needs assessment to create a logic model of the
problem
The needs assessment identified clinic-, provider- and parent-level barriers
to HPV vaccination to inform a logic model for HPV vaccination. This
comprised the following: 1) rates of HPV vaccination among adolescents in
the pediatric network compared to national rates; 2) perceived barriers,
attitudes, and practices regarding clinic organization and provider-related
factors impacting HPV vaccination; 3) perceived barriers, attitudes, beliefs,
and needs regarding HPV vaccine among parents of adolescents in the
pediatric network, and 4) current national best practices regarding HPV
vaccine promotion and strategies for incorporating HPV vaccination best
practices into clinical settings. Quantitative and qualitative methods
included literature review, analysis of cumulative vaccination data from the
electronic health record (EHR), interviews with clinic leaders, focus groups
with providers and staff in the 6 advisory clinics, and surveys with providers
and staff across the network.
Literature review
Conducted in 2014 in collaboration with a research librarian, the literature
review provided background on 1) current rates and burden of HPV
infection, and 2) evidence-based strategies to increase vaccination rates
and the clinical, behavioral, and psychosocial factors associated with their
implementation. Inclusion criteria comprised articles published in peerreviewed journals, including review articles and surveys as well as practice
guidelines. Abstracts, poster presentations, and editorial publications were
excluded. Electronic publication databases comprised PubMed, EMBASE,
and MEDLINE. The Community Preventive Services Task Force’s
Community Guide8 provided a systematic review of the evidence of
effectiveness of health promotion strategies that was foundational for this
study. Strategies included provider assessment and feedback (A&F),
provider cues, provider communication strategies (e.g., bundled
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messaging), and patient reminders. Evidence tables were developed for
expert review. The literature review provided information on national
immunization recommendations to prevent HPV, system factors in clinic
settings that facilitate provider recommendations for HPV vaccination
initiation, and physician-level factors affecting parent decision making to
accept HPV vaccination recommendations. Critical findings that informed
the AVP are provided in Table 2.
Analysis of cumulative vaccination data from the electronic medical
record
HPV vaccine initiation and completion rates were assessed for all patients
ages 11-17 seeking care at the 51-clinic pediatric network from January 1
through December 31, 2013. Among 92,735 patients over the 12-month
period, overall HPV vaccine initiation was 49.4%. HPV vaccine initiation
among girls was 54.0%, and among boys the rate was 44.9%. Overall
completion rate for the HPV vaccine series was 24.2%. The completion rate
was 30.3% among girls and 18.3% among boys. These rates fall far below
the Healthy People 2020 goal of 80%. In the recommended 11- to 12-year
age group, overall HPV vaccine initiation was 39.1%. For girls ages 11-12,
HPV vaccine initiation was 42.0%; for boys it was 36.3%. Additionally, 44%
of physicians had an HPV vaccine uptake rate less than 50%; 22% had an
uptake rate less than 40%; and over 7% had an uptake rate less than 30%.
In contrast, vaccination rates for tetanus, diphtheria, and pertussis (Tdap)
and meningococcal vaccine (MCV) exceeded 91%.
Interviews with clinic leaders in 5 advisory clinics
Site leaders and practice managers and 14 clinic leaders were interviewed
at 5 of the advisory clinics. Interviews were recorded and transcribed.
Information was obtained on leadership roles and responsibilities, clinic
workflow, current vaccine practices and protocols to adjust to changes in
vaccine recommendations, barriers to HPV vaccination, and suggested
strategies to increase HPV vaccination. The network’s expectation was for
clinics to adhere to national standards (ie, ACIP), but there was significant
variation in delivery of HPV recommendations between clinics and between
physicians and medical assistants (MAs).
Focus groups with providers and staff in the 6 advisory clinics
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In-person focus groups were conducted with 78 staff members within the
advisory clinics. Group size ranged from 9 to 18. Participants included 22
pediatricians, 15 MAs, 14 nurses, 10 certified medical assistants (CMAs), 6
front desk/reception staff, 5 practice managers, and 1 assistant director,
clinical supervisor, physician assistant, X-ray technician, triage worker, and
referral specialist. Each focus group was recorded and thematically
analyzed. Focus group findings informed the AVP development and
encompassed themes related to how the vaccine was introduced, provider
barriers to recommending the vaccine, and parental barriers to the vaccine
(Table 3).
Surveys with providers and staff across the network
Online surveys were distributed to all clinical staff at each clinic in the
network (n=51) to assess baseline perceptions of HPV vaccine. The 30minute surveys were completed by clinical staff (nurses, physician
assistants, and MAs) (n=375; response rate: 88.7%), practice managers
(n=45; response rate: 90%), and physicians (n=134; response rate: 59.7%).
The survey focused on physician experiences with the HPV vaccine and
addressed organization and patient barriers that they encounter when
vaccinating adolescents. The surveys comprised items with fixed format
response options including 4-point Likert scales with varied response
options (Strongly Agree/Strongly Disagree; Not at all a barrier/A major
barrier, etc.).24 Providers were asked to select responses most
representative of their experience. Analysis by the project team determined
that lower initiation rates were mainly associated with physician concerns
about parents’ negative perceptions about the HPV vaccine, the vaccine’s
safety, its efficacy, and the financial burden the vaccine places on patients 24
(Figure 1).
Task 1.3: Describe the context for the intervention including the
population, setting, and community
The AVP was developed for implementation in primary care clinics within a
large pediatric network (previously described). The heterogeneity offered
across the 51 clinics (size, location, time within the network) and the patient
population (demographics, insurance status) provided an excellent test-bed
for development. The priority environmental focus was the clinical
organization and the provider. A parent-facing educational program is
described elsewhere. Community sentiment regarding vaccination in
general, and HPV vaccination in particular, were acknowledged as
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important environmental influences in vaccine decision making (Figure 1).
However, broader community influencers, while important, were outside the
scope of the project.
Table 2. Literature review key findings
Key Finding
System factors are
a major
determinant of
receiving HPV
vaccination.

The research on
provider attitudes
and practices
describes several
sources of provider
hesitancy to
recommend or
discuss the HPV
vaccine with
parents.
Physician
recommendation
remains an
important
determinant in
parents’ decision to
vaccinate their
child.29,41-43

Qualifications
Primary parental determinants of HPV vaccination
initiation among adolescents were talking with a doctor,
having enough time to discuss the vaccine, having a
healthcare provider recommend it, and having a
healthcare visit in the past year.25-28 Parents express a
strong preference to receive information about HPV
vaccination directly from trusted healthcare providers.29-31
Common sources of provider hesitancy include providers’
“perception that younger adolescents are less at risk of
HPV so vaccination can be delayed,” providers’
perceptions of parental hesitancy and ambivalence,
misunderstanding parental barriers to vaccination,22,32 and
limited time with patients.33-38 Furthermore, delaying
discussion of HPV vaccination leads to missed
opportunities39 because younger adolescents (11-14
years) are 3 times more likely to attend preventive visits
than older adolescents.40
The CDC estimates that HPV vaccination initiation would
reach over 90% if providers’ recommendations for HPV
vaccination were similar to their recommendations for
other adolescent vaccines.5 Commensurate with this is
that providers convey vaccine recommendations
consistent with evidence-based guidelines; provide
accurate, evidence-based information about HPV and
HPV vaccine; reassure patients of high vaccine safety
due to ongoing postlicensure safety surveillance; and
reinforce the message that the HPV vaccine is
recommended despite not being required for school.

https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/9
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Table 3. Focus group key findings
#

Category

Findings

1

Introducing
the HPV
vaccine

2

Provider
barriers

3

Parental
barriers

Providers tended to differentiate HPV vaccine from other
vaccines recommended at the 11- to 12-year-old visit,
presenting tetanus and diphtheria (Tdap) and
meningococcal vaccine (MCV) as required for school but
framing HPV as optional, either consciously or
subconsciously. Most providers appeared reluctant to
pursue the topic of HPV vaccination if the parent was
hesitant or resistant, especially for younger children.
Practices varied on whether the physician or clinical
support staff first introduced the HPV vaccine and whether
the parent received the Vaccine Information Statement
(VIS) at the beginning or the end of the visit.
Providers, particularly MAs, stated their own concerns as
insufficient knowledge about HPV and HPV-related
diseases, the perception that there was no immediate need
to vaccinate younger adolescents, and not understanding
the rationale for HPV vaccination starting at age 11.
Providers stated that the most frequent concerns
expressed by parents were not knowing or understanding
the diseases the HPV vaccine prevents, wanting to wait
until the child was older (child not having sex), wanting to
wait until more was known about the long-term effects
(vaccine was too new), and wanting to think about it or
discuss it with their spouse.
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Figure 1. Logic model of the problem: Health care provider determinants of provider behaviors and
parent outcomes
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Task 1.4: State program goals
The goal of the AVP was to use a multicomponent strategy to enable clinics
to meet national metrics for HPV vaccination initiation and completion. This
entailed enabling clinicians, providers, and staff members to adopt and
implement evidence-based strategies to increase HPV vaccination.
Respective organizational, provider/staff, and patient goals for the AVP
included the following:
1. Primary care pediatric clinics that adopt and implement the AVP will
demonstrate a significant increase in HPV vaccination initiation and
completion rates in the clinic during implementation compared to rates
prior to implementation.
2. Providers and staff who adopt and implement AVP-related behaviors
within their clinic will demonstrate a significant increase in their patients’
HPV vaccination initiation and completion rates during implementation
compared to rates prior to implementation.
3. Children who attend clinics implementing the AVP will be more likely to
receive the HPV vaccination after implementation than they were prior
to implementation of the AVP.
IM STEP 2: PROGRAM OUTCOMES AND OBJECTIVES – LOGIC
MODEL OF CHANGE
Step 2 comprised the following: identification of expected outcomes,
performance objectives, and determinants of the behavior and environment;
the development of matrices of change objectives; and the construction of
a logic model of change for the AVP.13 This step enabled the triangulation
of data obtained in Step 1 (from theory, empirical findings, and participant
involvement) to inform a logic model of change.
Task 2.1: State expected outcomes for behavior and environment
Expected Behavioral Outcomes. The AVP was designed to positively
impact the adoption and implementation of evidence-based strategies to
increase HPV vaccination rates in primary care pediatric clinics. The
expected behavioral outcome was that pediatricians will vaccinate eligible
patients against HPV in accordance with ACIP guidelines. Targeted health
and quality-of-life outcomes included impact on health status (decreased
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sexually transmitted infection [STI] and cancer incidence, reduced
hospitalizations), functional status (increased future productive days at
work, enhanced functioning and relationships), and long-term impacts
(reduced societal cost of years of life lost, medical care, and long-term care
costs) (Figure 2).
Expected Environmental Outcomes. The AVP was designed to enable
clinics to adopt evidence-based strategies (AVP champions, assessment
and feedback, provider education, provider cues, and patient reminders) as
usual practice.
Task 2.2: Specify performance objectives for health-promoting
behavior and environmental outcomes
Performance objectives (PO) for adoption and implementation of
evidence-based HPV vaccination strategies in the AVP
Performance objectives comprised the following: collaborate with the
clinic’s champions on immunization status updates and strategies regarding
HPV vaccination (PO.1); review quarterly assessment and feedback reports
for HPV vaccination (PO.2); coordinate with clinical support staff to ensure
that consistent messaging is delivered to patients regarding HPV
vaccination (PO.3); check vaccine eligibility (Forecaster database) at every
encounter to identify if patient is eligible for vaccination (PO.4); deliver
strong recommendation for HPV vaccination to all eligible patients at time
of visit (PO.5a); bundle the HPV vaccine recommendation with other
vaccines when the patient is due for other vaccinations at the same visit
(PO.5b); determine specific patient/parent concern if they express vaccine
hesitancy (PO.6); communicate tailored messages to address specific
patient/parent concerns (PO.7); and remind patients to schedule follow-up
HPV vaccine dose(s) before leaving the office (PO.8) (Figure 2).
Task 2.3: Select determinants for behavioral and environmental
outcomes
Findings from the empirical literature, relevant theory (ie, Social Cognitive
Theory,44 Theory of Reasoned Action,45 Health Belief Model46) and prior
formative research (Task 1.2 above) informed selection of behavioral
determinants. These comprised knowledge, self-efficacy, outcome
expectations, skills, and normative beliefs as important and changeable for
providers to perform AVP-related performance objectives (Table 4).
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Figure 2: Logic Model of Change for AVP
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Table 4. Health care provider matrix of performance objectives, determinants, and change objectives.
Behavioral outcome: Physicians will vaccinate eligible patients against HPV in accordance with ACIP guidelines
Performance
Objectives

Behavioral Determinants*
Knowledge

PO.1. Collaborate
with clinic’s
champion on AVP
strategies to
promote HPV
vaccination

K.1a: Identify the designated AVP
champions in his/her clinic

PO.2. Review
quarterly
assessment and
feedback report for
HPV vaccination

K.2a: Identify when and how A&F
reports will be delivered

K.1b: Describe the role of AVP
champions as mediators for strategic
rollout of 4 strategies* in clinics

K.2b: Describe the content of the A&F
reports
K.2c: Recognize that A&F is one of
the most effective strategies to
promote vaccination

PO.3. Coordinate
with clinical support
staff to ensure
consistent
messaging is
delivered to
patients regarding
HPV vaccination

K.3a: Describe the difference
between consistent and inconsistent
messaging about HPV vaccination in
a clinic setting
K.3b: Recognize that inconsistent
messaging about HPV vaccination
occurs in clinics

Skills and Self-efficacy
SSE.1a: Demonstrate ability to
collaborate with clinic champion on
strategies* to promote HPV
vaccination

Outcome Expectations

Normative Beliefs

OE.1: Expect that collaborating with
clinic’s champion on HPV vaccine
promotion strategies will improve
personal and clinic-level HPV
vaccination rates

NB.1: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the network’s expectation for
optimal physician performance

OE.2a: Expect that reviewing A&F
reports will allow his/her clinic and
staff to track progress toward HPV
vaccination goals

NB.2: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance

SSE.1b: Express confidence in ability
to collaborate with clinic champion on
strategies* to promote HPV
vaccination
SSE.2a: Demonstrate ability to state
personal and clinic-level vaccine rates
from a quarterly A&F report
SSE.2b: Demonstrate ability to state
personal HPV vaccination goal for the
following quarter

OE.2b: Expect that reviewing A&F
reports will improve personal and
clinic-level HPV vaccination rates

SSE.2c: Express confidence in ability
to interpret A&F reports
SSE.3a: Demonstrate ability to
communicate with clinical staff about
consistent HPV vaccine messaging**
SSE.3b: Express confidence in ability
to communicate with clinical staff
about consistent HPV vaccine
messaging**

OE.3a: Expect that delivering
consistent messaging from all clinical
staff to patients will reduce
patient/parent resistance
OE.3b: Expect that delivering
consistent messaging from all clinical
staff to patients will improve personal
and clinic-level HPV vaccination rates

NB.3: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance

K.3c: Recognize that inconsistent
messaging about HPV vaccination

https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/9
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can lead to parental vaccine
hesitancy
PO.4. Check
forecaster at every
encounter to
identify if patient is
eligible for
vaccination

K.4a: List ACIP eligibility criteria for
HPV vaccination in adolescents

PO.5. Deliver
strong
recommendation
for HPV
vaccination to all
eligible patients at
time of visit

K.5a: Recognize HPV vaccination is
an effective cancer prevention tool

K.4b. Describe functions of
Forecaster
K.4c: Recognize that patients are less
likely to come back to doctor after age
13

K.5b: Recognize HPV vaccination is
safe and recommended by medical
organizations with the same strength
as other adolescent vaccines

SSE.4a: Demonstrate ability to check
forecaster in a timely manner to
determine patient vaccinations status
SSE.4b: Express confidence in ability
to check Forecaster in a timely
manner

SSE.5.1: Demonstrate ability to
deliver strong HPV vaccine
recommendation
SSE.5.2: Express confidence in ability
to deliver strong HPV vaccine
recommendation

K.5c: Describe components of a
strong HPV vaccine recommendation

OE.4a: Expect that identifying eligible
patients at every encounter will
reduce missed opportunities to
vaccinate
OE.4b: Expect that identifying eligible
patients at every encounter will
improve personal and clinic-level
HPV vaccination rates
OE.5a: Expect that delivering a
strong HPV vaccine recommendation
to all eligible patients will reduce
patient/parent resistance
OE.5b: Expect that delivering a
strong HPV vaccine recommendation
to all eligible patients will improve the
likelihood of patients initiating the
HPV vaccine series

NB.4: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance

NB.5a: Recognize that vaccinating
all eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance
NB.5b: Recognize that HPV
vaccination is widely endorsed by
medical organizations and other
physicians as a safe and effective
cancer prevention tool
NB.5c: Recognize that physicians
tend to overestimate the level of
hesitancy parents have about the
HPV vaccine

PO.5a. Bundle
HPV vaccine
recommendation
with other vaccines
when patient is due
for other
vaccinations at the
same visit

K.5a: Describe the difference
between a bundled HPV
recommendation and one that singles
out HPV from other vaccines
K.5b: Describe key elements of a
bundled HPV vaccine
recommendation
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SSE.5a.1: Demonstrate ability to
deliver bundled HPV vaccine
recommendation
SSE.5a.2: Express confidence in
ability to deliver bundled HPV vaccine
recommendation

OE.5a: Expect that bundling HPV
vaccine recommendation with other
vaccinations will reduce
patient/parent resistance
OE.5b: Expect that bundling HPV
vaccine recommendation with other
vaccinations will improve the

NB.5a: Recognize that vaccinating
all eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance
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likelihood of patients initiating the
HPV vaccine series
PO.6. Determine
specific
patient/parent
concern if they
express vaccine
hesitancy

K.6a: List common parental concerns
related to vaccine hesitancy

PO.7.
Communicate
tailored message to
address specific
patient/parent
concern

K.7: Describe key talking points to
address common parental concerns
related to vaccine hesitancy

PO.8. Remind
patients to
schedule 2nd and
3rd HPV vaccine
dose before leaving
the office

K.8a: Describe CDC’s recommended
dosing schedule for the HPV vaccine
series
K.8b: Recognize the importance of
series completion for optimal cancer
prevention benefits

SSE.6a: Demonstrate ability to
identify specific patient/parent
concerns related to HPV vaccination

OE.6a: Expect that identifying specific
patient/parent concerns will save time
in vaccine discussions

SSE.6b: Express confidence in ability
to identify specific patient/parent
concerns

OE.6b: Expect that identifying specific
patient/parent concerns will improve
the likelihood of patients initiating the
HPV vaccine series

SSE.7a: Demonstrate ability to deliver
tailored message to patients/parents
about their specific vaccination
concerns

OE.7a: Expect that delivering tailored
messages to address patient/parent
vaccination concerns will save time in
vaccine discussions

SSE.7b: Express confidence in ability
to deliver tailored message to
patients/parents about their specific
vaccination concerns

OE.7b: Expect that delivering tailored
messages to address patient/parent
vaccination concerns will improve the
likelihood of patients initiating the
HPV vaccine series

SSE.8a: Demonstrate ability to
remind patients to schedule 2nd and
3rd vaccine dose before leaving the
office

OE.8: Expect that reminding patients
to schedule their 2nd and 3rd HPV
vaccine dose will improve the
likelihood of patients completing the
HPV vaccine series

SSE.8b: Express confidence in ability
to remind patients to schedule 2nd and
3rd HPV vaccine dose before leaving
the office

NB.6: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance

NB.7: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance

NB.8: Recognize that vaccinating all
eligible patients against HPV in
accordance with ACIP guidelines is
part of the clinic network’s
expectation for optimal physician
performance

*Strategies include: Immunization Champions, Assessment and Feedback (A&F), CME, and Provider Cues.
**Communication with clinical staff should include ensuring they: present HPV vaccination with the same importance as other vaccines, bundle the introduction of HPV vaccine with
other vaccines when appropriate, and understand that physicians are looking to increase their vaccination rates and thus expect to vaccinate all eligible patients against HPV when
they come in for a visit.
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Task 2.4: Construct matrices of change objectives
Matrices were developed that cross-referenced behavioral performance
objectives with psychosocial determinants to produce change objectives
(Table 4). The resulting cells of each matrix contained change objectives.
Change objectives described the criteria for which a specific determinant
(eg, self-efficacy) could positively influence a specific performance
objective.
Task 2.5: Create a logic model of change
The resultant logic model provided an encapsulated understanding of the
functional components required by the AVP to impact the provider
behaviors (Figure 2).
IM STEP 3: PROGRAM PLAN
Step 3 comprised the following: the generation of the AVP’s scope and
sequence, the choice of theory- and evidence-based methods, and the
design of practical applications to deliver change methods. Step 3 tasks
were informed by evidence tables constructed in Step 1 and from the
research team’s collective academic and clinical experience. Regular
planning group meetings and brainstorming informed the AVP plan.
Task 3.1: Generate program themes, components, scope, and
sequence
The theoretical framework for the AVP is based in Social Cognitive
Theory,44 Theory of Reasoned Action,45 the Health Belief Model,46 clinical
guidelines for HPV vaccination,4 and empirical evidence drawn from the
review of literature on evidence-based strategies to increase HPV
vaccination rates. The development challenge was to meet both the clinic
provider and staff needs in a format for easy institutionalization within
clinics. Components. Intervention components comprised the following:
immunization champions, A&F reports, provider online continuing education
(CE), EHR provider cues, and parent vaccination reminders (Figure 3).
Design documents and schematics were produced by the project team,
reviewed by stakeholders, and piloted with providers in situ in advisory
clinics prior to implementation (detailed in task 4.4 below). Scope. AVP
scope was defined by evidence-based strategies shown to be efficacious in
increasing HPV vaccination rates in clinic settings. Provider interviews
(described previously) and observation of clinic workflow suggested the
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scope and sequence of the AVP functions and rollout (Figure 3) and is
described in detail in step 4 below. Theme. The AVP was designed as a
sequential rollout of strategies with minimal disruption to clinic flow. The title
Adolescent Vaccination Program (AVP) was initially a working title during
development. Despite having broader connotations beyond HPV, the name
stuck during field testing.
Task 3.2: Choose theory- and evidence-based change methods
Individual Behaviors
Theoretically and empirically based methods varied for each AVP
component. Methods included assessment of HPV vaccination behaviors,
feedback on HPV vaccination rates, reinforcement for behavioral
successes, goalsetting to address improvement in HPV vaccination rates,
advance organizers and cues for real-time alerts to instigate HPV
vaccinations, self-monitoring of HPV vaccination behaviors, facilitation and
linkage to skills training, and technical support as needed (Table 5). The
project team selected methods based on empirical evidence for their use to
impact the target determinants (exemplified in Tables 1 and 2).13
Clinic Environment
Quality-of-Care Measures. Published quality-of-care measures for clinical
practice were consulted to determine context of use for the AVP. The AVP
was aligned with the Healthy People 2020 Guideline and HEDIS
benchmarks of 80% vaccination for eligible patients. HEDIS metrics for
quality of care have been adopted as best-practice standards for U.S.
clinics.23 Clinic Task Analysis. Task analysis was conducted in each of the
participating clinics to examine data flow within the clinic, provider decision
making, interaction points between the patient and provider or clinic staff,
and interaction with the EHR. This identified logical opportunities for
adoption and implementation of evidence-based strategies (Figure 4).
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Figure 3. AVP: System rollout of evidence-based strategies into network clinics
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Table 5. Example of methods and practical applications used in AVP to impact determinants for vaccination
behavior
Behavioral outcome: Physicians will vaccinate eligible patients against HPV in accordance with ACIP guidelines
Performance objective: PO2. Review quarterly assessment and feedback (A&F) report for HPV vaccination
# Objective
KNOWLEDGE
K.2a: Identify when and how A&F reports will be delivered
K.2b: Describe the content of the A&F reports
K.2c: Recognize that A&F is one of the most effective
strategies to promote vaccination

Method

Practical Application

Skill building and guided
practice

Champions receive one champion binder to hold A&F reports, newsletters, and
information about webinars for providers to access.

Chunking

Champions send logs recording each provider’s receipt of the A&F report back
to the project team.

Tailoring
Feedback
Consciousness raising

SKILLS AND SELF-EFFICACY
SSE.2a: Demonstrate ability to state personal and clinic-level
vaccine rates from a quarterly A&F report

Elaboration

SSE.2b: Demonstrate ability to state personal HPV vaccination
goal for the following quarter

Goal setting

SSE.2c: Express confidence in ability to interpret A&F reports

Tailoring

Reinforcement

Champions educate providers about the effectiveness of A&F reports.
Providers engage in CEs, which provide education regarding the effectiveness of
A&F reports.
A&F reports colorful images, graphs, and tailored reports to display information
about clinic- and provider-level vaccination rates.
Clinic-level reports provide vaccination rates for each provider in the clinic and
the clinic’s rate in comparison to all other network clinics.
Provider-level reports include messaging and badges to encourage providers
who have met ACIP vaccine and initiation and completion goals to continue their
strong work in cancer prevention.
Provider-level reports inform providers when they have not met their vaccination
prevention and completion goals and provide the number of additional
vaccination initiations and completions needed to meet ACIP goals in the coming
quarter.

OUTCOME EXPECTATIONS
OE.2a: Expect that reviewing A&F reports will allow his/her
clinic and staff to track progress toward HPV vaccination goals
OE.2b: Expect that reviewing A&F reports will improve
personal and clinic-level HPV vaccination rates
NORMATIVE BELIEFS
NB.2: Recognize that vaccinating all eligible patients against
HPV in accordance with ACIP guidelines is part of the clinic
network’s expectation for optimal physician performance
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Self-assessment

Quarterly A&F reports are stored in the champion binder for tracking provider
and clinic vaccination rate progress from quarter to quarter.

Persuasive communication

Physician newsletters from the clinic network director provides messaging
regarding the network’s vaccination initiation and completion goals.

Information about others’
approval
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FIGURE 4. Clinic task analysis flow.
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Task 3.3: Select or design practical applications to deliver change
methods
Practical applications were selected to operationalize the theory-based
change methods in ways that fit the population and setting. The AVP was
designed for easy adoption by clinic providers and staff. The champions
provided an acknowledged point of contact, an “embedded” advocate for
the AVP, and a mediator for delivery of AVP strategy rollout. Clinic
information technology was used to provide online CE training (through
HealthStream, the online portal for provider education within the clinical
network), provider cues for HPV vaccination eligibility (through Epic), and
patient reminder notifications (through MyChart). This is discussed further
in Task 5.3.
IM STEP 4: PROGRAM PRODUCTION
Step 4 comprised refinement of the AVP’s structure and organization,
planning for program materials, drafting of messages and materials, and
pretesting, refinement, and production of materials.13
Task 4.1: Refine program structure and organization
Evidence-based provider-level strategies, previously described in the
empirical literature (step 1), informed the development and adaptation of
AVP component strategies. The AVP included an implementation strategy
(AVP champions embedded in each clinic) and 4 evidence-based
interventions (goal-based A&F, provider education, provider reminders, and
tailored patient reminders) that provide strong evidence when used in
combination. A description of each strategy and its implementation are
described below.
AVP champions
Immunization champions are an implementation strategy. They serve as
advocates of the AVP and as mediators for rollout of evidence-based
strategies. They distribute A&F reports to physicians (physician report) and
clinic staff (nurses, physician assistants, and MAs) and clinic managers
(clinic level report), promote CE completion, and announce implementation
of provider reminders. Two AVP champions were selected per clinic and
typically comprised 1 site leader or physician and 1 clinical supervisor or
clinic staff member. Champion recruitment comprised an email sent from
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the clinic network’s CMO requesting AVP champions be instituted.
Champions participated in four 30-minute lunchtime webinar trainings that
occurred prior to each strategy rollout. Webinars comprised the following:
1) an overview of project goals and objectives; 2) evidence-based
strategies; 3) how to implement and monitor intervention strategies; 4)
resources and technical support from the project team; and 5) Q&A.
Webinars were conducted live and recorded for later use. AnyMeeting, an
online platform for webinar delivery, was used to host the webinars. The
same physician who narrated the provider education modules recorded the
narration for champion webinars. Champions received a binder to store
resources to assist AVP implementation. The binders included an overview
of the AVP, contact lists of the project team, a directory of all champions
within the clinic, an introduction from the CMO, A&F reports from each
quarter, printed webinars (including PowerPoint slides), fact sheets,
information about future webinars and initiatives, and resources (Qlikview
tutorial and CDC HPV tip sheet for health care providers, promotional flyers,
and tracking forms).
Assessment and Feedback reports
A&F reports were designed for physicians, clinic managers, and clinic staff
to evaluate their past and current vaccine rates (Figure 5). Reports provided
to clinic staff and practice managers contained clinic-level data (clinic
vaccination rates) while reports provided to physicians also contained
personalized information on vaccination performance and vaccination
goals. Content of the physician reports was particularly informed by CDC’s
Assessment, Feedback, Incentives, and Xchange (AFIX) program
strategies for improving HPV vaccination. SAC feedback guided iterative
development of the report including data presented, layout, colors, and
messaging. A&F reports comprised the following: 1) vaccine trends (Tdap,
MCV, HPV) across the network clinics, 2) quarterly vaccination rates for
each clinic, and 3) quarterly vaccination rates for each provider. Metrics
included percentage of eligible patients who have ever received vaccines
for Tdap, MCV, or HPV, and percentage of patients who have completed
the HPV vaccine series. Also included were tailored text summaries for
each provider comprising either a target goal (ie, “To meet the national goal
of 80% HPV vaccination over the next year, you need to initiate at LEAST
___ patients per quarter”) or a reinforcement if the provider reached 80%
HPV series initiation, 60% series completion, or both (ie, “WOW! Thank you
for your OUTSTANDING work in Cancer Prevention! Keep up the good
work!”). Providers who initiated or completed the HPV series equal to or
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above these goals also received a badge of recognition. Clinics meeting the
80% initiation criterion also received a badge stating: “All doctors >80%
HPV Series Initiation.” Qlikview, an application within the network’s EHR
system, was used to generate and refine monthly data by the project team
statistician, who translated this into graphic displays for inclusion in the
quarterly A&F reports. The team delivered the reports to clinic champions,
who distributed them to each physician within their clinic in February, May,
August, and November.
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Figure 5. Assessment and feedback reports
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Figure 5 (continued)
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Provider education
A comprehensive online continuing education (CE) for doctors (continuing
medical education, CME) and nurses (continuing nursing education, CNE)
was developed for network pediatricians, nurses, and clinical staff (Figure
6). CE objectives were to: 1) inform providers about emerging HPV
vaccination guidelines and new initiatives being implemented by the
network, and 2) provide skills to help providers engage with and motivate
patients/parents to adhere to vaccination schedules. Content comprised the
following: 1) ethical principles in HPV vaccination; 2) about HPV; 3) latest
guidelines on the HPV vaccination; 4) evidence-based strategies for
increasing HPV vaccination; and 5) recommended communication
strategies (e.g., assertive bundled recommendations) and rolling with
resistance when parents are vaccine-hesitant. A network physician
provided voice narration. The finalized CE was reviewed by the SAC and
accepted by the accreditation board of the network for credit approval. Clinic
network leadership approved the HPV training module for 1 hour of ethics
CE credit. A medical ethicist collaborated with the team to incorporate ethics
principles (e.g., the principle of justice encompasses the need to
recommend HPV vaccination equally and universally to all eligible patients).
Ethics credit provided further incentive. Provider CE was implemented in
the form of a self-paced CE module delivered through HealthStream, an
online content management system.
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Figure 6. Provider continuing education
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Provider reminders
Provider behavioral cues comprised Best Practice Advisory (BPA) alerts to
enable providers and staff to easily identify age-eligible patients due or
overdue for HPV vaccination. The BPAs were developed in collaboration
with the clinic network’s EHR team, including the physician developer of
pre-existing asthma and flu BPAs, and informed by CDC guidelines (Figure
7). The algorithm for the alert system comprised the following: 1) alert for
first HPV vaccine (HPV-1) if patient is a female 12-26 years of age or male
12-21 years of age AND has no prior HPV vaccination; 2) alert for second
HPV dose (HPV-2) if patient is female or male 12-26 years of age AND
received HPV-1 before 15 years of age AND 6 months or more have passed
since HPV-1 vaccine OR patient is female or male 12-26 years of age AND
received HPV-1 at 15 years of age or older AND 1 month or more has
passed since HPV-1; and 3) alert for third dose of HPV vaccine (HPV-3) if
patient is female or male 12-26 years of age AND received HPV-1 at 15
years of age or older AND 4 months or more have passed since HPV-2
vaccine. While ACIP recommends routine HPV vaccine initiation beginning
at age 11, the network preferred to commence the BPA alerts beginning at
age 12. BPA alerts commenced at age 12 because HPV vaccination was
already considered standard care for the 11-year-old visit, when the vaccine
is included in the order set. The BPAs were added to the Epic system and
modified to reflect updates in CDC guidelines, most notably in 2017 when
the 2-dose schedule for adolescents under 16 years of age was released.
During clinical encounters with a patient who is due or overdue for HPV
vaccination, an alert appears in the patient’s EHR, prompting the provider
to initiate HPV vaccination. The BPA system sends alerts during both wellchild and sick visits. Alerts contain a link to order the vaccine and multiple
response options for case records: done, ordered, patient declined, patient
not eligible, discussed, or not addressed.
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Figure 7. Provider reminders

Patient reminders
The American Academy of Pediatrics (AAP) reminder and recall systems
guidelines informed the development of reminder messages for parents
with vaccine-eligible children (Figure 8). Messages were developed to
remind parents to Initiate the HPV vaccine and to schedule 2nd and, as
appropriate, 3rd doses. Messages followed existing formatting standards
used by the network and were reviewed for content by the SAC before being
incorporated into an automatic messaging system. Patients who were
identified as 10 years and 11 months of age through 17 years and vaccine
eligible were flagged to receive targeted reminders. This was done using an
existing Pediatric Wellness Registry integrated within the network’s Epic
and MyChart systems. Automated messages were sent 1 month before the
child’s HPV vaccine due date. Parents were able to see their upcoming due
date for their child’s HPV immunization on the Preventive Care page in
MyChart, the patient-facing application of the Epic EHR.
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FIGURE 8. Patient reminders
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Task 4.2: Prepare plans for program materials
AVP design documents provided a blueprint of the functional specifications
and rollout sequence of each strategy (Figure 3). Project team conference
calls and face-to-face meetings provided iterative review and feedback on
the design. Design documents described content, design features,
functionality, language, logistics of use and implementation in the clinic,
orientation needs, and evaluation specifications. The SAC had few
concerns about the use of the AVP within the clinics, recommending only
minor modifications to layout, clarity of content, and ease of access for
minimal disruption to clinic services.
Task 4.3: Draft messages, materials, and protocols
Program drafting followed a stepped sequence. Each component draft built
upon the iterative review of previous developmental drafts, allowing multiple
reviews. Strategies were developed for deployment using pre-existing
delivery platforms: CE provider education on narrated PowerPoint slides on
HealthStream, Epic cues as programming logic for inclusion in the Epic
EHR, and patient reminders as text statements formatted for insertion into
MyChart email announcements (discussed further in Task 5.3).
Task 4.4: Pretest, refine, and produce materials
Each AVP strategy prototype was pretested and refined through an inhouse review and, as amenable, a feasibility pilot test in the 6 advisory
clinics.
AVP review by the SAC. The AVP project team and SAC previewed AVP
content and function for consistency with clinic mission and professional
protocols, and for anomalies such as logical inconsistencies, illegibility, or
unappealing format. Review was conducted in regular meetings or via email. Feedback was collated and approved by the project directors prior to
feasibility testing.
AVP component feasibility testing in advisory clinics. Advisory clinics
followed protocols to select an AVP champion and rolled out provider
assessment and feedback over a 2-week period. Champions completed
logs recording any problems encountered. One champion was interviewed
at each of the 6 stakeholder clinics. Champions expressed satisfaction with
the process and their role in distributing and tracking the assessment and
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feedback reports, and the champions noted that physicians liked the reports
and were interested in comparing their rates with others. Champion
recommendations led to protocol adjustments to deliver reports at the
beginning of the month prior to monthly meetings and to provide a 2-week
window to return Distribution Logs.
IM STEP 5: IMPLEMENTATION PLAN
Step 5 comprised the description of potential program implementers,
defining the outcomes and performance objectives for implementation,
constructing matrices of change objectives for implementation, and
designing implementation interventions.13
Task 5.1: Identify potential program implementers
The AVP was designed for use by pediatric primary care clinic providers
and staff. Potential adopters included the director of the pediatric network,
clinic directors, providers (pediatricians), and clinic managers.
Task 5.2: State
implementation

outcomes

and

performance

objectives

for

Performance objectives for adoption were brainstormed by the project team
with consideration of the decision-makers in the network and informed by
the IM framework13 and characteristics for diffusion of innovation.47
Outcomes included that implementers would recognize a need for the AVP
and its relative advantage and would make a formal commitment to use
information technology (IT). Steps for implementation included that the
clinic network director would assess the need for a program to initiate
strategies to increase HPV vaccination, review the AVP and its components
and note objectives and relative advantages for its adoption, obtain
feedback from clinic staff on potential barriers to/advantages of adopting the
AVP, and agree to trial the AVP components.
Task 5.3: Construct matrices of change objectives for implementation
& Task 5.4: Design implementation interventions
Critical opportunities for AVP strategy implementation within the clinics
were identified using clinic task analysis (previously described). This also
helped identify existing IT channels by which to deploy the strategies (Table
6). Matrices categorized objectives for the network CMO to implement the
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AVP across the network and for the champions to implement the AVP within
their clinic (Table 7). The AVP is more likely implemented if it is minimally
disruptive to clinic activities or clinic overhead. Advantages of the AVP
include its provision of resources and protocols with established feasibility
and a requirement of only a single investment of resource (mainly staff time
commitment) to set up an A&F report structure, CE program access, Epic
cuing setup, and parent reminder message blasts. This upfront commitment
is offset by significant increases in HPV vaccination rates that approach
HEDIS benchmarks.
IM STEP 6: EVALUATION PLAN
Step 6 comprised effect and process evaluation questions, developing
indicators and measures of assessment, and specifying an evaluation
design.
Task 6.1: Write effect and process evaluation questions
The primary question to be addressed in planning the evaluation of the AVP
was: Does the use of the AVP within a primary prevention pediatric clinical
network over a 3-year period increase HPV vaccine initiation and
completion rates? Stated as an alternative testable empirical hypothesis: A
clinical network that uses the AVP in the context of their usual clinic
operations over a 3-year period will demonstrate significantly higher rates
of HPV vaccine initiation and completion compared to rates prior to AVP
implementation. Planned process evaluation questions included
assessment of factors that mediate the success of the AVP as well as
facilitating its implementation. These include intervention exposure (number
of A&F reports received, number of providers and staff completing the CE);
impact on patient-provider communication (change to a bundled vaccine
recommendation); application of provider cues within the EHR; and
institution of patient reminders.
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Table 6. Processes and channels for deployment of AVP strategies
HPV
STRATEGIES
Immunization
champions

Assessment and
feedback (A&F)
report

Provider
continued
education

Provider
Reminders
Parent Reminder
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IMPLEMENTATION CHANNELS
DEPLOYMENT (including IT platforms)
• Live training webinars (30 min) using AnyMeeting preceded each
strategy rollout. System enabling session recording and attendance
tracking.
• Champion binders and materials were mailed via the network mail
system.
Champions notified clinic personnel in • Reports were generated after accessing data via a Qlikview portal
regular meetings.
within the EHR.
• Printed reports were delivered to champions via the network mail
service. Champions distributed reports in clinic meeting or mailboxes
at their discretion.
• Champions kept an additional copy of each A&F report in their binder
and kept a distribution log for tracking.
CE promotion by:
The CE was deployed online through HealthStream, the network’s
online learning system, and was accessible throughout the study.
• Champions in regular meetings;
• Promotional flyer included with each
A&F report;
• Network CMO in monthly
newsletters.
Champions notified clinic personnel in Provider reminder best-practice alerts (BPAs) were included in the Epic
regular meetings.
EHR.
Champions were updated in webinar
MyChart, a patient facing component of the Epic EHR, sent automated
and notified clinics in regular
content and messaging to all patients listed in an existing Wellness
meetings.
Registry (updated nightly) that identified vaccine- and age-eligible
patients. Quarterly reports tracked the number of reminders sent.
PROMOTION
Champions were notified of webinar
trainings by e-mail.
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Table 7. Matrix of key stakeholders/gatekeepers for implementation
Performance
Objectives
AVP Strategy
To facilitate
Implementation
of …
Assessment and
Feedback (A&F)
Reports

Implementation Stakeholder
Knowledge

Network CMO
Skills and SelfOutcome
efficacy
Expectations

Normative
Beliefs

Knowledge

Clinic Champion
Skills and SelfOutcome
efficacy
Expectations

Normative
Beliefs

K.CMO.A&F:
Recognize the
content of A&F
reports, their
source data, and
optimal
implementation.

SSE.CMO.A&F:
Demonstrate
ability to promote
A&F reports
across the
network via
regional meetings
and monthly
newsletters.

OE.CMO.A&F:
Expect that A&F
reports will lead
to increased
awareness of
individual-,
clinic-, and
network-level
vaccine rates.

NB.CMO.A&F:
Recognize that
A&F reports
can move the
network’s
culture toward
prioritizing HPV
vaccination.

K.Champ.A&F:
Recognize the
content of A&F
reports, their
source data,
and optimal
implementation
in the clinic.

SSE.Champ.A&F:
Demonstrate
ability to promote
and distribute
A&F reports via
clinic meetings
and/or report
distribution.

OE.Champ.A&F:
Expect that A&F
reports will lead
to increased
awareness of
individual-, clinic, and networklevel vaccine
rates.

NB.Champ.A&F:
Recognize that
A&F reports can
move the clinic’s
culture toward
prioritizing HPV
vaccination.

Continued
Education (CE)

K.CMO.A&F:
Recognize the
content of CE,
source data, and
optimal
implementation
in the network.

OE.CMO.A&F:
Expect that CE
will lead to
increased HPVrelated
knowledge and
skills of network
personnel.

SSE.Champ.A&F:
Demonstrate
ability to promote
the CE via clinic
meetings and/or
flyer distribution
and ensure
linkage.

OE.Champ.A&F:
Expect that CE
will lead to
increased HPVrelated
knowledge and
skills of clinic
personnel.

NB.Champ.A&F:
Recognize that
CE can increase
the clinics’
collective
awareness and
skills for HPV
vaccination.

K.CMO.A&F:
Recognize the
content of PCs,
their logic,
source data, and
optimal
implementation
in the network.

K.Champ.A&F:
Recognize the
content of PCs,
source data,
and optimal
implementation
in the clinic.

SSE.Champ.A&F:
Demonstrate
ability to promote
via clinic
meetings and/or
notice distribution.

OE.Champ.A&F:
Expect that PCs
will lead to
decreased
missed
opportunities for
HPV vaccination
within the clinic.

NB.Champ.A&F:
Recognize that
PCs are a
component of
optimal clinic
performance to
meet national
HPV vaccination
guidelines.

Parent
Reminders
(PRs)

K.CMO.A&F:
Recognize the
content of PRs,
their source data,
layout, and
optimal
implementation
in the network.

NB.CMO.A&F:
Recognize that
CE can
increase the
network’s
collective
awareness and
skills for HPV
vaccination.
NB.CMO.A&F:
Recognize that
PCs are a
component of
optimal network
performance to
meet national
HPV
vaccination
guidelines.
NB.CMO.A&F:
Recognize that
PRs are a
component of
optimal network
performance to
meet national
HPV
vaccination
guidelines.

K.Champ.A&F:
Recognize the
content of CE,
source data,
and optimal
implementation
in the clinic.

Provider Cues
(PCs)

SSE.CMO.A&F:
Demonstrate
ability to promote
the CE reports
across the
network via
regional meetings
and monthly
newsletters.
SSE.CMO.A&F:
Demonstrate
ability to promote
PCs across the
network via
regional meetings
and monthly
newsletters and
facilitate inclusion
in EHR..
SSE.CMO.A&F:
Demonstrate
ability to promote
PRs across the
network via
regional meetings
and monthly
newsletters and
facilitate inclusion
in MyChart.

K.Champ.A&F:
Recognize the
content of PRs,
source data,
and optimal
implementation
in the clinic.

SSE.Champ.A&F:
Demonstrate
ability to promote
PRs via clinic
meetings and/or
notice distribution.

OE.Champ.A&F:
Expect that PRs
will lead to
increased
appointments for
HPV vaccination
in the clinic.

NB.Champ.A&F:
Recognize that
PRs are a
component of
optimal network
performance to
meet national
HPV vaccination
guidelines.
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OE.CMO.A&F:
Expect that PCs
will lead to
decreased
missed
opportunities for
HPV vaccination
across the
network.
OE.CMO.A&F:
Expect that PRs
will lead to
increased
appointments
for HPV
vaccination
across the
network.
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Task 6.2: Develop indicators and measures for assessment
Evaluation of the AVP focused on collection of centralized data on
vaccination initiation and completion of the HPV vaccine measured as a
binary variable (yes/no). Initiation was defined as receiving at least 1 dose
of the HPV vaccine. Completion was defined as receiving 3 doses in years
2014 and 2015 and as receiving 2 or 3 doses, depending on age at initiation,
for 2016-2017. This dosage change corresponded with the updated
guideline that went into effect in October 2016. Quarterly rates were
calculated at physician and clinic levels, and annual rates were calculated
for all clinics combined. AVP data were compared to state-level data from
the National Immunization Survey (NIS)-Teen for the years 2014, 2015, and
2016.48 An age group reported by NIS-Teen (13-17 years) was the primary
comparison with the network in order to evaluate the effect of secular trends.
Planned process measures to assess implementation fidelity were specified
for each strategy. These included a champion attendance log (to indicate
attendance at webinars), a provider signoff sheet (to indicate receipt of
assessment and feedback reports by providers), a back-end data base (to
record CE use by providers and clinic staff), test results from the network IT
(to confirm accuracy and ongoing functionality of EHR-based cues), and
reports on number of vaccination reminders sent to parents of vaccineeligible youth. Plans also included records of any reported refusal to adopt
strategies or barriers to implementation whether organizational or logistic.
Task 6.3: Specify evaluation design
The evaluation design for the AVP was an ecological single-group pre-/posttest evaluation within the 51-clinic network. A randomized design could not
be implemented without contamination across study conditions. Further, the
funding mechanism focused primarily on delivery of services and
evaluation, and secondarily on research. The systems-based rollout of the
AVP components took place within all 51 clinics simultaneously. Providers
and staff in each clinic were invited to complete the baseline survey prior to
AVP rollout and again at the end of the evaluation period. Cumulated
vaccination rate data were assessed at baseline and quarterly throughout
the project in order to give feedback to the physicians and clinics on their
A&F reports. Clinics then rolled out the AVP strategies according to a
sequenced timeline. Primary analysis involved comparisons of changes in
vaccination rates from baseline through 4 years using logistic regression.
Limitations of the evaluation design are those of internal validity because a
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quasi experimental design has no randomization or comparison group.
Although this design can establish a trend, it cannot definitively attribute
results to the AVP alone. However, it is noteworthy that the AVP was
associated with significant increases in HPV vaccination initiation and
completion rates even after considering state-level secular trends based on
the NIS-Teen.12
DISCUSSION
The AVP is a successful HPV vaccination program designed to address the
need identified in the Community Guide for implementation of evidencebased strategies to increase HPV vaccination initiation and completion
rates and to increase rates to be commensurate with those of Tdap and
MCV, targeting HEDIS criteria of 80%. It is also responsive to the Healthy
People 2020 objective to increase the proportion of persons receiving HPV
vaccination.6
The IM framework was used to design the AVP due to its potential utility in
developing multilevel systems-based approaches. Advantages of the
framework include the imposition of a systematic approach; thoroughness
in detailing needs and solutions informed by theoretical and empirical
literature; encouraging critical thinking regarding implementation,
evaluation, and dissemination; and ensuring that priority populations were
consulted throughout. The IM framework is built to accommodate the use
of theories designed to inform development of behavioral change
interventions (eg, Social Cognitive Theory,44 Theory of Reasoned Action,45
Health Belief Model46) as well as those designed to inform the development
and packaging of implementation strategies that facilitate the use of
interventions within clinics (eg, Diffusion of Innovation47.
Consolidated Framework for Implementation Research).48,49
The resulting components of AVP are theory- and evidence-based,
packaged into a product that can be integrated into an existing clinic
network’s workflow and technology system. Though many of the
components found in this study have been used previously, they are
independently insufficient; combining them with other evidence-based
components and a novel parent educational app reflects the next generation
of interventions to increase HPV vaccine rates.
Other interventions focused on HPV vaccine rates have been effective to a
varying extent. Though many interventions have tested the efficacy and
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effectiveness of one component or one level of an HPV intervention,9 this is
the first intervention to our knowledge to use IM to develop a successful
multilevel intervention focused on increasing HPV vaccine rates in a
pediatric clinic setting. To date, there is a lack of ubiquitous adoption and
implementation of evidence-based practices. The current study targets the
provider and clinic levels to influence behavioral and system-level changes.
The current study has several strengths. First, a comprehensive team of
experts and potential participants on the provider level developed the
intervention using dynamic feedback from those who could benefit most
from the intervention’s components. Second, the intervention received
strong “buy-in” from the participating pediatric network, which provides
health care for a significant portion of the city’s pediatric care population.
Third, the intervention was developed to address needs at organizational,
provider, and patient levels, which contribute to a higher likelihood of
behavior change than focusing on one level alone.9,50
Findings need interpretation in light of study limitations. The generalizability
of the AVP is unknown because it was developed with the participation of
one pediatric network and limited to a single geographic urban area.
However, by utilizing one of the largest pediatric networks in the U.S.,
including 51 clinics of various size, this study helps build evidence of
feasibility and acceptability across diverse clinic settings. Further, while the
evaluation of the AVP suggests success in terms of increasing HPV vaccine
rates, the relative efficacy and impact of each individual component on the
outcomes of our intervention are unclear.
The AVP development presented here represents one case study
application for a systems-based intervention in a clinical context. In this
capacity, it provides a guide for future development in analogous domains,
populations, and applications. However, in practice the degree of fidelity to
IM core processes varied with each development task. The formality of
posing questions, brainstorming answers, reviewing findings from published
research, accessing and using theory, identifying and addressing the need
for new research, and formulating the working list of answers varied among
components of A&F, CE, cues, and reminders dependent on project
constraints and existing practices. Also, the evaluation plan was limited to
the period of study and did not include an assessment of sustainability in
the long term. IM was conducive to providing an innovative multicomponent
approach to implementing evidence-based strategies within primary care
pediatric clinics. By providing evidence-based tools and procedures for
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identifying and assisting clinics to increase HPV vaccination rates, this study
contributes to the national goal.
CONCLUSION
Limited impact of current interventions to increase use of HPV vaccine
among adolescents represents a missed opportunity to prevent multiple
types of HPV-related cancer. IM provided a framework to develop a
multilevel, multicomponent intervention aimed at clinic system, providers,
and parents to promote implementation of evidence-based strategies to
increase HPV vaccine uptake and completion among adolescents ages 1117. The AVP’s feasibility for clinic use and efficacy in increasing HPV
vaccination in a large pediatric clinic network in the southwestern United
States is testament to the utility of IM as a framework for development of
systems-based interventions.
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Future directions
Future directions for the AVP include determining overall initiation and
completion outcomes and testing dissemination and implementation for use
among other clinic networks. The AVP is currently being expanded to a
smaller pediatric clinic network in the same state. Of note, members of the
original clinic network in this study have requested assistance with
permanent adoption of AVP components for sustainability within the clinics.
This interest in the AVP suggests that broader dissemination is indicated.
FUNDING
This project was funded by Prevention Grant #PP140183 and Research
Grant #RP150014 from the Cancer Prevention and Research Institute of
Texas (CPRIT).
ACKNOWLEDGMENTS:
We extend our deepest appreciation to the patients and clinicians who
participated in the development and testing of the Adolescent Vaccination
Program and to the support of the Cancer Prevention and Research
Institute of Texas (CPRIT). This project received human research approval
from the local human subject research institutional review boards at the
University of Texas Health Science Center at Houston (UTHealth) and
Baylor College of Medicine.
CONFLICT OF INTEREST STATEMENT:
The authors declare that this project was conducted in the absence of any
commercial or financial relationships that could be construed as a potential
conflict of interest. The authors and their academic institutions have
received no payment or services from a third party for any aspect of this
project. There are no financial relationships with organizations or entities
that could be perceived to influence, or that give the appearance of
potentially influencing, what has been written in this work. No commercial
patents or copyrights are or have been pending, issued, licensed, and/or
received and no royalties have been received from this project.

Published by DigitalCommons@TMC, 2019

41

Journal of Applied Research on Children: Informing Policy for Children at Risk, Vol. 10 [2019], Iss. 2, Art. 9

REFERENCES
1.

2.

3.

4.

5.

6.

7.

8.

9.

10.
11.

Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted
infections among US women and men: prevalence and incidence
estimates, 2008. Sex Transm Dis. 2013;40(3):187-193.
Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV
types in cancers: implications for current and 9-valent HPV
vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
Viens LJ, Henley SJ, Watson M, et al. Human papillomavirusassociated cancers--United States, 2008-2012. MMWR Morb
Mortal Wkly Rep. 2016;65(26):661-666.
Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human
papillomavirus (HPV) vaccine: updated HPV vaccination
recommendations of the advisory committee on immunization
practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-304.
Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus
vaccination coverage among adolescents, 2007-2013, and
postlicensure vaccine safety monitoring, 2006-2014--United States.
MMWR Morb Mortal Wkly Rep. 2014;63(29):620-624.
Office of Disease Prevention and Health Promotion. Healthy People
2020. https://www.healthypeople.gov/2020/topicsobjectives/topic/immunization-and-infectious-diseases/objectives.
Accessed May 19, 2020.
Walker TY, Elam-Evans LD, Singleton JA, et al. National, regional,
state, and selected local area vaccination coverage among
adolescents aged 13-17 years--United States, 2016. MMWR Morb
Mortal Wkly Rep. 2017;66(33):874-882.
Centers for Disease Control and Prevention. The Guide to
Community Preventive Services. Increasing Appropriate
Vaccination https://www.thecommunityguide.org/topic/vaccination.
Accessed May 19, 2020.
Smulian EA, Mitchell KR, Stokley S. Interventions to increase HPV
vaccination coverage: a systematic review. Hum Vaccin
Immunother. 2016;12(6):1566-1588.
Walling EB, Benzoni N, Dornfeld J, et al. Interventions to improve
HPV vaccine uptake: a systematic review. Pediatrics. 2016;138(1).
Glanz K, Bishop DB. The role of behavioral science theory in
development and implementation of public health interventions.
Annu Rev Public Health. 2010;31:399-418.

https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/9

42

Crawford et al.: Intervention Mapping: Developing a Systems-Based HPV Intervention

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

Vernon SW, Savas L, Shegog R, et al. The adolescent vaccination
program: increasing pediatric HPV vaccination initiation and
completion with a systems-based intervention. 2020. In review.
Bartholomew Eldredge LK, Markham CM, Ruiter RAC, Fernández
ME, Kok G, Parcel GS. Planning Health Promotion Programs: An
Intervention Mapping Approach. 4th ed. San Francisco,CA: JosseyBass Inc; 2016.
Garba RM, Gadanya MA. The role of intervention mapping in
designing disease prevention interventions: a systematic review of
the literature. PLoS One. 2017;12(3):e0174438.
Tripp MK, Herrmann NB, Parcel GS, Chamberlain RM, Gritz ER.
Sun Protection is Fun! A skin cancer prevention program for
preschools. J Sch Health. 2000;70(10):395-401.
Dalum P, Schaalma H, Kok G. The development of an adolescent
smoking cessation intervention--an intervention mapping approach
to planning. Health Educ Res. 2012;27(1):172-181.
Fernandez ME, Gonzales A, Tortolero-Luna G, Partida S,
Bartholomew LK. Using intervention mapping to develop a breast
and cervical cancer screening program for Hispanic farmworkers:
Cultivando La Salud. Health Promot Pract. 2005;6(4):394-404.
Byrd TL, Wilson KM, Smith JL, et al. Using intervention mapping as
a participatory strategy: development of a cervical cancer screening
intervention for Hispanic women. Health Educ Behav.
2012;39(5):603-611.
Byrd TL, Wilson KM, Smith JL, et al. AMIGAS: a multicity,
multicomponent cervical cancer prevention trial among Mexican
American women. Cancer. 2013;119(7):1365-1372.
Hou SI, Fernandez ME, Parcel GS. Development of a cervical
cancer educational program for Chinese women using intervention
mapping. Health Promot Pract. 2004;5(1):80-87.
Rodriguez SA, Roncancio AM, Savas LS, Lopez DM, Vernon SW,
Fernandez ME. Using intervention mapping to develop and adapt
two educational interventions for parents to Increase HPV
vaccination among Hispanic adolescents. Front Public Health.
2018;6:164.
Hofstetter AM, Vargas CY, Kennedy A, Kitayama K, Stockwell MS.
Parental and provider preferences and concerns regarding text
message reminder/recall for early childhood vaccinations. Prev
Med. 2013;57(2):75-80.

Published by DigitalCommons@TMC, 2019

43

Journal of Applied Research on Children: Informing Policy for Children at Risk, Vol. 10 [2019], Iss. 2, Art. 9

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

National Committee for Quality Assurance. Healthcare
Effectiveness Data and Information Set (HEDIS) accreditation.
https://www.ncqa.org/hedis/measures/. Accessed May 19, 2020.
Farias AJ, Savas LS, Fernandez ME, et al. Association of
physicians perceived barriers with human papillomavirus
vaccination initiation. Prev Med. 2017;105:219-225.
Rahman M, Laz TH, McGrath CJ, Berenson AB. Correlates of
human papillomavirus vaccine completion among adolescent girl
initiators. Clin Pediatr (Phila). 2015;54(14):1328-1333.
Kepka D, Ding Q, Hawkins AJ, Warner EL, Boucher KM. Factors
associated with early adoption of the HPV vaccine in US male
adolescents include Hispanic ethnicity and receipt of other
vaccines. Prev Med Rep. 2016;4:98-102.
Moss JL, Reiter PL, Rimer BK, Brewer NT. Collaborative patientprovider communication and uptake of adolescent vaccines. Soc
Sci Med. 2016;159:100-107.
Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley
S. Barriers to human papillomavirus vaccination among US
adolescents: a systematic review of the literature. JAMA Pediatr.
2014;168(1):76-82.
Etter DJ, Zimet GD, Rickert VI. Human papillomavirus vaccine in
adolescent women: a 2012 update. Curr Opin Obstet Gynecol.
2012;24(5):305-310.
Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel
R, Tooher RL. Factors associated with HPV vaccine uptake in
teenage girls: a systematic review. Vaccine. 2012;30(24):35463556.
De Jesus M, Parast L, Shelton RC, et al. Actual vs preferred
sources of human papillomavirus information among black, white,
and Hispanic parents. Arch Pediatr Adolesc Med.
2009;163(11):1066-1067.
Healy CM, Montesinos DP, Middleman AB. Parent and provider
perspectives on immunization: are providers overestimating
parental concerns? Vaccine. 2014;32(5):597-584.
McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy:
findings from a statewide survey of health care providers. J Pediatr
Health Care. 2014;28(6):541-549.
Hswen Y, Gilkey MB, Rimer BK, Brewer NT. Improving physician
recommendations for human papillomavirus vaccination: the role of
professional organizations. Sex Transm Dis. 2017;44(1):43-48.

https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/9

44

Crawford et al.: Intervention Mapping: Developing a Systems-Based HPV Intervention

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.
45.
46.

Dempsey AF, Lockhart S, Campagna EJ, Pyrzanowski J, Barnard
J, O' Leary ST. Providers' time spent and tools used when
discussing the HPV vaccine with parents of adolescents. Vaccine.
2016;34(50):6217-6222.
Kasting ML, Wilson S, Dixon BE, Downs SM, Kulkarni A, Zimet GD.
Healthcare providers' beliefs and attitudes regarding risk
compensation following HPV vaccination. Papillomavirus Res.
2016;2:116-121.
Scherr CL, Augusto B, Ali K, Malo TL, Vadaparampil ST. Providerreported acceptance and use of the Centers for Disease Control
and Prevention messages and materials to support HPV vaccine
recommendation for adolescent males. Vaccine. 2016;34(35):42294234.
Hughes CC, Jones AL, Feemster KA, Fiks AG. HPV vaccine
decision making in pediatric primary care: a semi-structured
interview study. BMC Pediatr. 2011;11:74.
Vadaparampil ST, Kahn JA, Salmon D, et al. Missed clinical
opportunities: provider recommendations for HPV vaccination for
11-12 year old girls are limited. Vaccine. 2011;29(47):8634-8641.
Rand CM, Shone LP, Albertin C, Auinger P, Klein JD, Szilagyi PG.
National health care visit patterns of adolescents: implications for
delivery of new adolescent vaccines. Arch Pediatr Adolesc Med.
2007;161(3):252-259.
Bartlett JA, Peterson JA. The uptake of human papillomavirus
(HPV) vaccine among adolescent females in the United States: a
review of the literature. J Sch Nurs. 2011;27(6):434-446.
Reiter PL, Katz ML, Paskett ED. Correlates of HPV vaccination
among adolescent females from Appalachia and reasons why their
parents do not intend to vaccinate. Vaccine. 2013;31(31):31213125.
Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence
parental vaccination decisions for adolescents, 13 to 17 years old:
National Immunization Survey-Teen, 2010. Clin Pediatr (Phila).
2013;52(2):162-170.
Bandura A. Human agency in social cognitive theory. Am Psychol.
1989;44(9):1175-1184.
Fishbein M. A reasoned action approach to health promotion. Med
Decis Making. 2008;28(6):834-844.
Hochbaum GM. Public Participation in Medical Screening
Programs: A Socio-psychological Study. Washington, DC: US Dept
of Health, Education, and Welfare; 1958.

Published by DigitalCommons@TMC, 2019

45

Journal of Applied Research on Children: Informing Policy for Children at Risk, Vol. 10 [2019], Iss. 2, Art. 9

47.
48.

49.

50.

Rogers E. Diffusion of Innovations. 5th ed. New York, NY: Simon
and Schuster; 2003.
Centers for Disease Control and Prevention. NIS - Teen Data Adolescents/Teens (13-17 years).
https://www.cdc.gov/vaccines/imzmanagers/coverage/nis/teen/index.html. Accessed May 19, 2020.
Tabak RG, Khoong EC, Chambers D, Brownson RC. Bridging
research and practice: models for dissemination and
implementation research. Am J Prev Med. 2012;43(3):337-350.
Fiks AG, Grundmeier RW, Mayne S, et al. Effectiveness of decision
support for families, clinicians, or both on HPV vaccine receipt.
Pediatrics. 2013;131(6):1114-1124.

https://digitalcommons.library.tmc.edu/childrenatrisk/vol10/iss2/9

46

